Pfizer und BioNTech veröffentlichen neue Daten zu verbesserter Immunantwort gegenüber aufkommenden Omikron-Sublinien nach Auffrischungsimpfung mit dem an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff
November 18, 2022 06:45 ET
|
BioNTech SE
Einen Monat nach einer 30-µg-Auffrischungsdosis mit dem an Omikron BA.4/BA.5 angepassten bivalenten COVID-19-Impfstoff stiegen die neutralisierenden Antikörpertiter gegen sich jüngst verbreitende...
Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages
November 18, 2022 06:45 ET
|
BioNTech SE
One month after a 30-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine, neutralizing antibody titers against emerging Omicron sublineages increased 3.2- to 4.8-fold compared...
Mendus AB: Mendus publicerar prekliniska data som visar signifikanta anti-tumorala synergier mellan intratumoral immunaktivering och inhibition av CTLA-4
July 14, 2022 02:00 ET
|
Mendus AB
Intratumoral injektion av allogena pro-inflammatoriska dendritceller (”ilixadencel”) inducerar en markant ökning av en för övrigt ineffektiv systemisk behandling med anti-CTLA-4 i en etablerad...
Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition
July 14, 2022 02:00 ET
|
Mendus AB
Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in an established...
Immunicum AB: Immunicum publicerar resultat från fas II MERECA-studien med Ilixadencel vid njurcancer i European Urology Open Sciences
April 28, 2022 02:00 ET
|
Immunicum AB
Immunicum AB (“Immunicum” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på behandlingar mot tumörrecidiv och svårbehandlade etablerade tumörer, har publicerat studieresultaten från Fas II...
Immunicum AB: Immunicum Publishes Phase II MERECA Trial Results of Ilixadencel in Kidney Cancer in European Urology Open Sciences
April 28, 2022 02:00 ET
|
Immunicum AB
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, has published the results of the Phase II...
Livanta Launches New Publication, The Livanta Claims Review Advisor, for Healthcare Providers
April 14, 2022 15:30 ET
|
Livanta LLC
ANNAPOLIS JUNCTION, Md., April 14, 2022 (GLOBE NEWSWIRE) -- To share general review findings and to offer related insight to healthcare organizations, Livanta LLC ("Livanta") is pleased to launch...
Immunicum publicerar verkningsmekanismen för DCP-001 i tidskriften Cells
November 22, 2021 02:00 ET
|
Immunicum AB
Pressmeddelande22 november 2021 Immunicum publicerar verkningsmekanismen för DCP-001 i tidskriften CellsImmunicum AB (publ; IMMU.ST), ett biofarmaceutiskt företag fokuserat på svårbehandlade solida...
Immunicum Publishes DCP-001 Mechanism of Action in the Journal Cells
November 22, 2021 02:00 ET
|
Immunicum AB
Press ReleaseStockholm, Sweden, November 22, 2021Immunicum Publishes DCP-001 Mechanism of Action in the Journal CellsImmunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat...
Diverse: Issues In Higher Education Launches Revamped Website Marking Nearly Half a Century of Publishing
November 17, 2021 14:59 ET
|
Diverse Education
Fairfax, Va., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Diverse: Issues In Higher Education has revitalized its online platform – improving the visitor experience, increasing partner visibility and...